Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)

4D Molecular Therapeutics (FDMT) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $103.0 million as the latest value for Q4 2019.

  • Quarterly Preferred Stock Liabilities changed N/A to $103.0 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $103.0 million through Dec 2019, changed N/A year-over-year, with the annual reading at $103.0 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2019 was $103.0 million at 4D Molecular Therapeutics.
  • The five-year high for Preferred Stock Liabilities was $103.0 million in Q4 2019, with the low at $103.0 million in Q4 2019.